Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Immuneering Corporation

Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
Immuneering to Present at the Morgan Stanley Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
Immuneering to Present at the Jefferies Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
Immuneering Announces $30 Million Underwritten Offering
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
Immuneering Appoints Harold E. Brakewood as Chief Business Officer
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
Immuneering Announces Participation in March Investor Conferences
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
Immuneering To Present at Guggenheim 2023 Oncology Conference
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
Immuneering Presents Promising Preclinical Data on its Second Program IMM-6-415 at the 37th Annual Meeting of SITC
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
Immuneering Announces Participation in November Investor Conferences
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
Immuneering Appoints Leah R. Neufeld as Chief People Officer
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.